Summary
The most recent press release from Gilead Scienes, Inc. (Nasdaq: GILD) re: phase III study of Darusentan, a novel endothelin receptor antagonist, designed to control resistant hypertension. The effectiveness in controlling systemic blood pressure was found to be statistically significant. Incidence of anemia and liver toxicity did not seem to be significant. Frequency of peripheral edema was remarkable.
Analysis
Darusentan can be useful in controlling hypertension when additional positive information, to offset phenomena of peripheral edema, becomes available.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
